Luis M. Vilá to Puerto Rico
This is a "connection" page, showing publications Luis M. Vilá has written about Puerto Rico.
Connection Strength
1.813
-
Serrano-Arroyo L, Gonz?lez-Mel?ndez A, R?os-Rivera R, Rodr?guez-Gonz?lez V, Vil? LM. Impact of SARS-CoV-2 pre-delta/delta and omicron variants on clinical outcomes in a systemic lupus erythematosus cohort from Puerto Rico. Lupus. 2025 Apr; 34(4):415-424.
Score: 0.166
-
Gonz?lez-Mel?ndez A, B?ez-Negr?n L, R?os-Rivera R, Franco-O'Connell AS, Nieves-Plaza M, Vil? LM. Short- and mid-term outcomes in systemic lupus erythematosus patients presenting with disease exacerbation after SARS-CoV-2 mRNA vaccination: A cohort study from Puerto Rico. Lupus. 2023 Apr; 32(4):571-579.
Score: 0.143
-
Medina-Cintr?n N, Mart?nez I, P?rez-R?os N, Berr?os-L?pez Y, Vil? LM. Clinical Manifestations and Outcomes in Disease-Modifying Antirheumatic Drug-Naive Adult Patients with Chronic Chikungunya Arthritis. Am J Trop Med Hyg. 2021 03 08; 104(5):1741-1746.
Score: 0.126
-
Jord?n-Gonz?lez P, Gago-Pi?ero R, V?zquez-Sanabria I, P?rez-R?os N, Vil? LM. Factors Associated With Disease Damage in Puerto Ricans With Primary Sj?gren Syndrome. J Clin Rheumatol. 2020 Oct; 26(7S Suppl 2):S101-S105.
Score: 0.122
-
V?zquez-Otero I, Medina-Cintr?n N, Arroyo-?vila M, Gonz?lez-Sep?lveda L, Vil? LM. Clinical impact of hydroxychloroquine dose adjustment according to the American Academy of Ophthalmology guidelines in systemic lupus erythematosus. Lupus Sci Med. 2020 05; 7(1).
Score: 0.119
-
Fred-Jim?nez RM, Arroyo-?vila M, Mayor ?M, R?os G, Vil? LM. Clinical Manifestations Associated with Overweight/Obesity in Puerto Ricans with Fibromyalgia Syndrome. J Obes. 2016; 2016:1379289.
Score: 0.088
-
Villafr?dez-D?az M, Santiago-Casas Y, Nieves-Plaza M, Morales M, Rodr?guez V, R?os G, Mart?nez D, Vil? LM. Association of the use of statins with disease activity and functional status in Puerto Ricans with rheumatoid arthritis. P R Health Sci J. 2014 Mar; 33(1):3-8.
Score: 0.077
-
Font YM, Castro-Santana LE, Nieves-Plaza M, Maldonado M, Mayor AM, Vil? LM. Factors associated with regional rheumatic pain disorders in a population of Puerto Ricans with diabetes mellitus. Clin Rheumatol. 2014 Jul; 33(7):995-1000.
Score: 0.077
-
D?az-Correa LM, Ram?rez-Garc?a LM, Castro-Santana LE, Vil? LM. Osteoporosis knowledge in patients with a first fragility fracture in Puerto Rico. Bol Asoc Med P R. 2014; 106(1):6-10.
Score: 0.076
-
Negr?n AM, D?az-Correa LM, Gago R, Mayor AM, Mart?nez A, Vil? S, Vil? LM. Rheumatology practice profiles in teaching and community settings in Puerto Rico: implications to subspecialty training. J Clin Rheumatol. 2013 Mar; 19(2):67-71.
Score: 0.072
-
Santiago-Casas Y, Gonz?lez-Rivera T, Castro-Santana L, R?os G, Mart?nez D, Rodr?guez V, Gonz?lez-Alcover R, Mayor AM, Vil? LM. Impact of managed care health insurance system for indigent patients with rheumatoid arthritis in Puerto Rico. Clin Rheumatol. 2013 Jun; 32(6):763-9.
Score: 0.072
-
Nieves-Plaza M, Castro-Santana LE, Font YM, Mayor AM, Vil? LM. Association of hand or knee osteoarthritis with diabetes mellitus in a population of Hispanics from Puerto Rico. J Clin Rheumatol. 2013 Jan; 19(1):1-6.
Score: 0.071
-
Nieves-Plaza M, Ortiz AP, Col?n M, Molina MJ, Castro-Santana LE, Rodr?guez VE, Mayor AM, Vil? LM. Outcome and predictors of kidney disease progression in Puerto Ricans with systemic lupus erythematosus initially presenting with mild renal involvement. J Clin Rheumatol. 2011 Jun; 17(4):179-84.
Score: 0.064
-
Castro-Santana LE, Col?n M, Molina MJ, Rodr?guez VE, Mayor AM, Vil? LM. Efficacy of two cyclophosphamide regimens for the treatment of lupus nephritis in Puerto Ricans: low vs. standard dose. Ethn Dis. 2010; 20(1 Suppl 1):S1-116-21.
Score: 0.058
-
Santiago-Casas Y, Gonz?lez-Rivera TC, Castro-Santana LE, R?os G, Mart?nez D, Rodr?guez VE, Gonz?lez-Alcover R, Mayor AM, Vil? LM. Impact of age on clinical manifestations and outcome in Puerto Ricans with rheumatoid arthritis. Ethn Dis. 2010; 20(1 Suppl 1):S1-191-5.
Score: 0.058
-
Negr?n AM, Molina MJ, Mayor AM, Rodr?guez VE, Vil? LM. Factors associated with metabolic syndrome in patients with systemic lupus erythematosus from Puerto Rico. Lupus. 2008 Apr; 17(4):348-54.
Score: 0.051
-
Molina MJ, Mayor AM, Franco AE, Morell CA, L?pez MA, Vil? LM. Utilization of health services and prescription patterns among lupus patients followed by primary care physicians and rheumatologists in Puerto Rico. Ethn Dis. 2008; 18(2 Suppl 2):S2-205-10.
Score: 0.050
-
Molina MJ, Mayor AM, Franco AE, Morell CA, L?pez MA, Vil? LM. Prevalence of systemic lupus erythematosus and associated comorbidities in Puerto Rico. J Clin Rheumatol. 2007 Aug; 13(4):202-4.
Score: 0.049
-
Vil? LM, Molina MJ, Mayor AM, Peredo RA, Santaella ML, Vil? S. Clinical and prognostic value of autoantibodies in puerto Ricans with systemic lupus erythematosus. Lupus. 2006; 15(12):892-8.
Score: 0.044
-
Vil? LM, Alarc?n GS, McGwin G, Bastian HM, Fessler BJ, Reveille JD. Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXIX. Elevation of erythrocyte sedimentation rate is associated with disease activity and damage accrual. J Rheumatol. 2005 Nov; 32(11):2150-5.
Score: 0.043
-
Mayor AM, Vil? LM. Gender differences in a cohort of Puerto Ricans with systemic lupus erythematosus. Cell Mol Biol (Noisy-le-grand). 2003 Dec; 49(8):1339-44.
Score: 0.038
-
Vil? LM, Alarc?n GS, McGwin G, Friedman AW, Baethge BA, Bastian HM, Fessler BJ, Reveille JD. Early clinical manifestations, disease activity and damage of systemic lupus erythematosus among two distinct US Hispanic subpopulations. Rheumatology (Oxford). 2004 Mar; 43(3):358-63.
Score: 0.038
-
Vil? LM, Mayor AM, Valent?n AH, Garc?a-Soberal M, Vil? S. Clinical and immunological manifestations in 134 Puerto Rican patients with systemic lupus erythematosus. Lupus. 1999; 8(4):279-86.
Score: 0.027
-
Willis R, Seif AM, McGwin G, Martinez-Martinez LA, Gonz?lez EB, Doan E, Dang N, Papalardo E, Liu J, Vil? LM, Reveille JD, Alarc?n GS, Pierangeli SS. Effects of statins on proinflammatory/prothrombotic biomarkers and on disease activity scores in SLE patients: data from LUMINA (LXXVI), a multi-ethnic US cohort. Clin Exp Rheumatol. 2014 Mar-Apr; 32(2):162-7.
Score: 0.019
-
Danila MI, Pons-Estel GJ, Zhang J, Vil? LM, Reveille JD, Alarc?n GS. Renal damage is the most important predictor of mortality within the damage index: data from LUMINA LXIV, a multiethnic US cohort. Rheumatology (Oxford). 2009 May; 48(5):542-5.
Score: 0.014
-
Alarc?n GS, McGwin G, Petri M, Ramsey-Goldman R, Fessler BJ, Vil? LM, Edberg JC, Reveille JD, Kimberly RP. Time to renal disease and end-stage renal disease in PROFILE: a multiethnic lupus cohort. PLoS Med. 2006 Oct; 3(10):e396.
Score: 0.012
-
Andrade RM, McGwin G, Alarc?n GS, Sanchez ML, Bertoli AM, Fern?ndez M, Fessler BJ, Apte M, Arango AM, Bastian HM, Vil? LM, Reveille JD. Predictors of post-partum damage accrual in systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (XXXVIII). Rheumatology (Oxford). 2006 Nov; 45(11):1380-4.
Score: 0.011
-
Uribe AG, Vil? LM, McGwin G, Sanchez ML, Reveille JD, Alarc?n GS. The Systemic Lupus Activity Measure-revised, the Mexican Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), and a modified SLEDAI-2K are adequate instruments to measure disease activity in systemic lupus erythematosus. J Rheumatol. 2004 Oct; 31(10):1934-40.
Score: 0.010
-
Alarc?n GS, McGwin G, Roseman JM, Uribe A, Fessler BJ, Bastian HM, Friedman AW, Baethge B, Vil? LM, Reveille JD. Systemic lupus erythematosus in three ethnic groups. XIX. Natural history of the accrual of the American College of Rheumatology criteria prior to the occurrence of criteria diagnosis. Arthritis Rheum. 2004 Aug 15; 51(4):609-15.
Score: 0.010
-
Robles RR, Reyes JC, Col?n HM, Matos TD, Vil? P?rez L, Marrero CA. Prevalence and correlates of anergy among drug users in Puerto Rico. Int J Epidemiol. 1999 Jun; 28(3):509-13.
Score: 0.007